Effect of porcine circovirus type 2 (PCV2) vaccination on porcine reproductive and respiratory syndrome virus (PRRSV) and PCV2 coinfection

Opriessnig, Tanja; Madson, Darin M.; Prickett, John; Kuhar, Daniel; Lunney, Joan K.; Elsener, Johanne; Halbur, Patrick G.

doi:10.1016/j.vetmic.2008.03.002

Cited by 78 publications

(56 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although effective PCV2 vaccines recently reached the market (Fachinger et al, 2008;Fort et al, 2008;Opriessnig et al, 2008), these products require additional labor and increased costs for producers. If a traceable genetic marker for PCVAD resistance were discovered, targeted breeding and genetic manipulation may facilitate reductions in PCVAD and negate the need for PCV2 vaccines in some swine herds.…”

Section: Discussionmentioning

confidence: 99%

Difference in severity of porcine circovirus type two-induced pathological lesions between Landrace and Pietrain pigs1

Opriessnig

Patterson

Madson

et al. 2009

Journal of Animal Science

Self Cite

View full text Add to dashboard Cite

Anecdotal information from the field suggests that there are host genetic differences in susceptibility to porcine circovirus type 2 (PCV2) associated disease among Landrace and Pietrain breeds. The objective of this study was to determine if a difference exists in PCV2 susceptibility between Landrace and Pi-etrain pigs under experimental conditions. Thirty-nine Landrace pigs and 39 Pietrain pigs were blocked by breed, sire, dam, and litter and randomly divided into the following 4 groups: Landrace noninoculated negative control (Landrace-NEG; n = 13), Pietrain noninoculated negative control (Pietrain-NEG; n = 13), Landrace-PCV2 (n = 26; Landrace), and Pietrain-PCV2 (n = 26; Pietrain). After waning of passively acquired anti-PCV2 antibodies, Landrace-PCV2 and Pietrain-PCV2 groups were inoculated with PCV2 isolate ISU-40895. The Landrace-NEG and Pietrain-NEG groups were housed in a separate room, remained noninoculated, and served as negative controls. All pigs in all groups were necropsied at 21 d post PCV2-inoculation. Onset of seroconversion and concentrations of anti-PCV2-IgM, anti-PCV2-IgG, and anti-PCV2 neutralizing antibodies were similar in Landrace-PCV2 and Pietrain-PCV2 groups. Furthermore, the amount of PCV2 DNA and cytokine concentrations in serum and plasma samples were not different between the 2 PCV2-inoculated groups. The severity of PCV2-associated microscopic lesions was different between Landrace and Pietrain pigs; Landrace-PCV2 pigs had significantly (P < 0.05) more severe lymphoid lesions than the Pietrain-PCV2 pigs. Although the pigs originated from the same farm where their dams were commingled, passively acquired anti-PCV2-antibodies waned in Pietrain pigs by approximately 12 wk of age, whereas the majority of the Landrace pigs remained PCV2 seropositive until 18 wk of age and beyond. The results from this study indicate that a genetic difference exists between these 2 breeds of pigs in susceptibility to PCV2-associated lesions. ABSTRACT: Anecdotal information from the field suggests that there are host genetic differences in susceptibility to porcine circovirus type 2 (PCV2) associated disease among Landrace and Pietrain breeds. The objective of this study was to determine if a difference exists in PCV2 susceptibility between Landrace and Pietrain pigs under experimental conditions. Thirty-nine Landrace pigs and 39 Pietrain pigs were blocked by breed, sire, dam, and litter and randomly divided into the following 4 groups: Landrace noninoculated negative control (Landrace-NEG; n = 13), Pietrain noninoculated negative control (Pietrain-NEG; n = 13), Landrace-PCV2 (n = 26; Landrace), and Pietrain-PCV2 (n = 26; Pietrain). After waning of passively acquired anti-PCV2 antibodies, Landrace-PCV2 and Pietrain-PCV2 groups were inoculated with PCV2 isolate ISU-40895. The Landrace-NEG and Pietrain-NEG groups were housed in a separate room, remained noninoculated, and served as negative controls. All pigs in all groups were necropsied at 21 d post PCV2-inoculation. Onset of seroconversion and ...

show abstract

Section: Discussionmentioning

confidence: 99%

Difference in severity of porcine circovirus type two-induced pathological lesions between Landrace and Pietrain pigs1

Opriessnig

Patterson

Madson

et al. 2009

Journal of Animal Science

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, the inactivated PCV2 vaccine was used in an extralabel manner to determine its effect against PCV2 shedding in semen from experimentally infected boars. The reduction in the PCV2 load is one of the criteria used to assess the efficacy of PCV2 vaccines (5,15). PCV2 vaccines decrease the PCV2 load in the serum and reduce PCV2 shedding in nasal and fecal samples in conventional pigs (5).…”

Section: Discussionmentioning

confidence: 99%

“…All PCV2 vaccines have been administered to either sows or piglets (2,5,16,18). Commercial PCV2 vaccines are able to reduce the PCV2 load in the serum and reduce PCV2 shedding in nasal and fecal samples in conventional pigs (5,15,16,18). Recently, it has also been reported that vaccination against PCV2 in naturally infected boars can decrease the duration of viral shedding in semen (1).…”

mentioning

confidence: 99%

Effects of an Inactivated Porcine Circovirus Type 2 (PCV2) Vaccine on PCV2 Virus Shedding in Semen from Experimentally Infected Boars

Seo

Han

Kim

et al. 2011

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

The objective of the present study was to determine the effect of an inactivated porcine circovirus type 2 (PCV2) vaccine on PCV2b virus shedding in the semen of experimentally infected boars by measuring the immunological response and the PCV2b DNA load in blood and semen. Twelve boars were randomly divided into three groups. The boars in group 1 (n ‫؍‬ 4) were immunized with an inactivated PCV2 vaccine and were challenged with PCV2b. The boars in group 2 (n ‫؍‬ 4) were only challenged with PCV2b. The boars in group 3 (n ‫؍‬ 4) served as negative controls. The number of PCV2 genome copies of PCV2 in the serum and semen were significantly lower in vaccinated challenged boars than in nonvaccinated challenged boars at 7, 10, 14, 21, 32, 35, 42, 49, and 60 days postinoculation. The number of PCV2b genomes in the semen correlated with the number of PCV2b genomes in the blood in both vaccinated challenged (R ‫؍‬ 0.714) and nonvaccinated challenged (R ‫؍‬ 0.861) boars. The results of the present study demonstrate that the inactivated PCV2 vaccine significantly decreases the amount of PCV2b DNA shedding in semen from vaccinated boars after experimental infection with PCV2b.Porcine circovirus type 2 (PCV2) is associated with a number of diseases and syndromes collectively referred to as porcine circovirus-associated disease (PCVAD), which includes postweaning multisystemic wasting disease (PMWS), porcine dermatitis and nephropathy syndrome (PDNS), reproductive failure, porcine respiratory disease complex (PRDC), and exudative epidermitis (3).Several commercial PCV2 vaccines are currently available in the global market. All PCV2 vaccines have been administered to either sows or piglets (2,5,16,18). Commercial PCV2 vaccines are able to reduce the PCV2 load in the serum and reduce PCV2 shedding in nasal and fecal samples in conventional pigs (5,15,16,18). Recently, it has also been reported that vaccination against PCV2 in naturally infected boars can decrease the duration of viral shedding in semen (1). These data strongly imply that vaccination against PCV2 may reduce the subsequent shedding of PCV2 in the semen of boars. Therefore, the objective of the present study was to determine the effect of PCV2 vaccination on the shedding of the PCV2 virus in the semen of experimentally infected boars. MATERIALS AND METHODSCommercial vaccine and PCV2 inoculum. The commercial inactivated tissue homogenate PCV2 vaccine based on PCV2 genotype 2b, CircoPrime (Komipharm International Company Ltd., Shiheung-shi, Kyongki-do, Republic of Korea), was used in this study. It was administered intramuscularly in two 2.0-ml doses separated by 3 weeks.The PCV2 strain (PCV2 genotype b) isolated from the superficial inguinal lymph node of a field case of PMWS was used as the inoculum. The virus was propagated in PCV-free PK15 cells to a titer of 10 5 50% tissue culture infective doses (TCID 50 s)/ml.Experimental design. At 8 months of age, 12 purebred, male, Landrace pigs were purchased from a commercial farm. All boars were negative for PCV2 and...

show abstract

“…Additionally, a protective effect of porcine parvovirus and erysipelas vaccination against PMWS was shown in piglets born to PCV2 infected sows, further supporting the idea that factors other than immune stimulation may be involved in clinical disease. Importantly, when PMWS is produced by a combination of PCV2 and PRRSV, although current vaccines against PCV2 are able to decrease the severity of PMWS-associated lesions, the vaccines alone are ineffective at completely diminishing the lesions to those of PRRSV infection alone (Opriessnig T MD, 2008). The contribution of the immune effects of each virus in producing clinical PMWS is unknown.…”

Section: Small Single-stranded Circular Dna Virusesmentioning

confidence: 99%

Regulatory T Cells and Viral Disease

LeRoith¹,

Ahmed²

2012

Inflammation, Chronic Diseases and Cancer - Cell and Molecular Biology, Immunology and Clinical Bases

View full text Add to dashboard Cite

Effect of porcine circovirus type 2 (PCV2) vaccination on porcine reproductive and respiratory syndrome virus (PRRSV) and PCV2 coinfection

Cited by 78 publications

References 32 publications

Difference in severity of porcine circovirus type two-induced pathological lesions between Landrace and Pietrain pigs1

Difference in severity of porcine circovirus type two-induced pathological lesions between Landrace and Pietrain pigs1

Effects of an Inactivated Porcine Circovirus Type 2 (PCV2) Vaccine on PCV2 Virus Shedding in Semen from Experimentally Infected Boars

Regulatory T Cells and Viral Disease

Contact Info

Product

Resources

About